INTRODUCTION: Macrophage migration inhibitory factor (MIF) is an inflammatory cytokine associated with acute and chronic inflammatory disorders and corticosteroid insensitivity. Its expression in the airways of patients with chronic obstructive pulmonary disease (COPD), a relatively steroid insensitive inflammatory disease is unclear, however. METHODS: Sputum, bronchoalveolar lavage (BAL) macrophages and serum were obtained from non-smokers, smokers and COPD patients. To mimic oxidative stress-induced COPD, mice were exposed to ozone for six-weeks and treated with ISO-1, a MIF inhibitor, and/or dexamethasone before each exposure. BAL fluid and lung tissue were collected after the final exposure. Airway hyperresponsiveness (AHR) and lung function were measured using whole body plethysmography. HIF-1α binding to the Mif promoter was determined by Chromatin Immunoprecipitation assays. RESULTS: MIF levels in sputum and BAL macrophages from COPD patients were higher than those from non-smokers, with healthy smokers having intermediate levels. MIF expression correlated with that of HIF-1α in all patients groups and in ozone-exposed mice. BAL cell counts, cytokine mRNA and protein expression in lungs and BAL, including MIF, were elevated in ozone-exposed mice and had increased AHR. Dexamethasone had no effect on these parameters in the mouse but ISO-1 attenuated cell recruitment, cytokine release and AHR. CONCLUSION: MIF and HIF-1α levels are elevated in COPD BAL macrophages and inhibition of MIF function blocks corticosteroid-insensitive lung inflammation and AHR. Inhibition of MIF may provide a novel anti-inflammatory approach in COPD.
INTRODUCTION: Macrophage migration inhibitory factor (MIF) is an inflammatory cytokine associated with acute and chronic inflammatory disorders and corticosteroid insensitivity. Its expression in the airways of patients with chronic obstructive pulmonary disease (COPD), a relatively steroid insensitive inflammatory disease is unclear, however. METHODS: Sputum, bronchoalveolar lavage (BAL) macrophages and serum were obtained from non-smokers, smokers and COPD patients. To mimic oxidative stress-induced COPD, mice were exposed to ozone for six-weeks and treated with ISO-1, a MIF inhibitor, and/or dexamethasone before each exposure. BAL fluid and lung tissue were collected after the final exposure. Airway hyperresponsiveness (AHR) and lung function were measured using whole body plethysmography. HIF-1α binding to the Mif promoter was determined by Chromatin Immunoprecipitation assays. RESULTS: MIF levels in sputum and BAL macrophages from COPD patients were higher than those from non-smokers, with healthy smokers having intermediate levels. MIF expression correlated with that of HIF-1α in all patients groups and in ozone-exposed mice. BAL cell counts, cytokine mRNA and protein expression in lungs and BAL, including MIF, were elevated in ozone-exposed mice and had increased AHR. Dexamethasone had no effect on these parameters in the mouse but ISO-1 attenuated cell recruitment, cytokine release and AHR. CONCLUSION: MIF and HIF-1α levels are elevated in COPD BAL macrophages and inhibition of MIF function blocks corticosteroid-insensitive lung inflammation and AHR. Inhibition of MIF may provide a novel anti-inflammatory approach in COPD.
Authors: T Calandra; B Echtenacher; D L Roy; J Pugin; C N Metz; L Hültner; D Heumann; D Männel; R Bucala; M P Glauser Journal: Nat Med Date: 2000-02 Impact factor: 53.440
Authors: Jodi B Lubetsky; Angeles Dios; Jialian Han; Bayan Aljabari; Bela Ruzsicska; Robert Mitchell; Elias Lolis; Yousef Al-Abed Journal: J Biol Chem Date: 2002-05-07 Impact factor: 5.157
Authors: T Calandra; J Bernhagen; C N Metz; L A Spiegel; M Bacher; T Donnelly; A Cerami; R Bucala Journal: Nature Date: 1995-09-07 Impact factor: 49.962
Authors: C Zhang; C Ramsey; A Berical; L Yu; L Leng; K A McGinnis; Y Song; H Michael; M C McCormack; H Allore; A Morris; K Crothers; R Bucala; P J Lee; M Sauler Journal: Am J Physiol Lung Cell Mol Physiol Date: 2018-12-06 Impact factor: 5.464
Authors: Milena Sokolowska; Valerie F J Quesniaux; Cezmi A Akdis; Kian Fan Chung; Bernhard Ryffel; Dieudonnée Togbe Journal: Front Immunol Date: 2019-09-13 Impact factor: 7.561
Authors: Marcin Mączyński; Andrzej Regiec; Aleksandra Sochacka-Ćwikła; Iwona Kochanowska; Maja Kocięba; Ewa Zaczyńska; Jolanta Artym; Wojciech Kałas; Michał Zimecki Journal: Pharmaceuticals (Basel) Date: 2021-05-15